Navigation Links
Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007
Date:1/31/2008

pared to 2006.

International sales increased 52%, including an 11% favorable foreign

exchange impact, to $169 million in the fourth quarter of 2007 from

$111 million in the same period in 2006 primarily due to increased

demand in Latin America and Europe.

-- Sales of the SUSTIVA(R) Franchise, a non-nucleoside reverse

transcriptase inhibitor for the treatment of HIV, increased 17%,

including a 5% favorable foreign exchange impact, to $260 million in

the fourth quarter of 2007 from $222 million in the same period in

2006. U.S. sales increased 13% to $162 million in the fourth quarter

of 2007 from $144 million in the same period in 2006, primarily due to

higher demand of ATRIPLA(TM). Estimated total U.S. prescription demand

increased approximately 15% compared to 2006. International sales

increased 26%, including a 13% favorable foreign exchange impact, to

$98 million in the fourth quarter of 2007 from $78 million in the same

period in 2006. Total revenue for the SUSTIVA(R) Franchise includes

sales of SUSTIVA(R), as well as revenue from bulk efavirenz included in

the combination therapy ATRIPLA(TM), which is sold through a joint

venture in the U.S. and Canada with Gilead Sciences, Inc.

-- Sales of BARACLUDE(R), an oral antiviral agent for the treatment of

chronic hepatitis B, increased 175%, including a 13% favorable foreign

exchange impact, to $99 million in the fourth quarter of 2007 from $36

million in the same period in 2006, due to continued growth across all

markets.

-- Sales of ORENCIA(R), a fusion protein indicated for adult patients with

moderate to severe rheumatoid arthritis launched in 2006, increased

134%, including a 3% favorable foreign exchange impact, to $75 million,

in the fourth quarter of 2007 from $32 million in the
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine news :

1. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
2. Bristol-Myers Squibb Names Alan J. Lacy to Board of Directors
3. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
4. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
5. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
6. Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
7. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
8. Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
9. Bristol-Myers Squibb Announces Dividend
10. P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company
11. First Pharmaceutical Company Comes to Hoboken, NJ: Swiss-Based Octapharma to Move U.S. Headquarters to SJP Properties Waterfront Corporate Center II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Raleigh, NC (PRWEB) , ... July 28, 2015 ... ... others cancers are more common in shipbreaking workers than they are in the ... Click here to read it now. , Researchers at Taiwan’s National ...
(Date:7/28/2015)... ... July 28, 2015 , ... Women fear developing Alzheimer's ... is that cancer, heart attack, and stroke are treatable, but there is little an ... do is to take part in a clinical trial, reports the July 2015 ...
(Date:7/28/2015)... CA (PRWEB) , ... July 28, 2015 , ... Every ... professionals or to use extreme caution when lighting fireworks in their own neighborhoods. Unfortunately, ... and discussed in a July 3, 2015 USA Today article " Eye Injuries Caused ...
(Date:7/28/2015)... ... 28, 2015 , ... A June 3, 2015 article ... Injury" discussed baseball player David Wright’s spinal stenosis injury and his chances of ... by degenerative changes in the spine, rather than congenital, which is good news ...
(Date:7/28/2015)... ... , ... Most employers have been using multi-tier prescription drug plans for many ... significant increase in the use of 4-tier plans, which typically cover the highest cost ... is expected to continue, according to UBA. , UBA’s survey finds that, since 2009, ...
Breaking Medicine News(10 mins):Health News:New Findings Suggest Mesothelioma is Not the Only Cancer Threat for Shipbreakers, According to Surviving Mesothelioma 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 2Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 3Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 2Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 2Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 4Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 5
... By Maureen Salamon HealthDay Reporter , WEDNESDAY, ... created equal, with women and men facing different heart risks ... a new study suggests. Analyzing the results of coronary ... blockages -- in 480 patients with acute chest pain, scientists ...
... by researchers at Cleveland Clinic published findings that indicate ... pain for an extended period of time. Fibronectin ... the survival, growth and communication of neurons in the brain ... animal model, that an injection of fibronectin into the spinal ...
... About 40 percent of young adults who,ve attempted suicide made ... thoughts and behavior may begin much younger than previously believed, ... ongoing survey, University of Washington researchers asked almost 900 young ... attempts. Nearly 9 percent (78) of the participants said ...
... HealthDay Reporter , WEDNESDAY, Nov. 30 (HealthDay News) -- Eating ... may boost brain health and lower the risk for mild ... The study authors found that eating baked and broiled ... matter neurons, strengthening them in areas of the brain deemed ...
... that world renowned neurosurgeon R. Michael Scott, MD, ... Distinguished Service Award. Given by the American Association ... the award is the highest honor given by ... advanced the field of pediatric neurosurgery. Alan Cohen, ...
... NY Scientists investigating the interactions, or binding patterns, ... the entire genome in normal human cells have turned ... The distinct binding patterns reflect differences in the chromatin ... be important for understanding the function of the tumor ...
Cached Medicine News:Health News:Clogged Arteries Pose Different Dangers for Men, Women: Study 2Health News:Clogged Arteries Pose Different Dangers for Men, Women: Study 3Health News:Cleveland researchers find possible breakthrough to relieve pain following spinal cord injury 2Health News:Many Suicidal Teens Make First Try Before High School 2Health News:Non-Fried Fish Might Help Ward Off Alzheimer's: Study 2Health News:Non-Fried Fish Might Help Ward Off Alzheimer's: Study 3Health News:R. Michael Scott, M.D., receives the Franc D. Ingraham Distinguished Service Award 2Health News:First analysis of tumor-suppressor interactions with whole genome in normal human cells 2Health News:First analysis of tumor-suppressor interactions with whole genome in normal human cells 3Health News:First analysis of tumor-suppressor interactions with whole genome in normal human cells 4
(Date:7/27/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... and commercializing proven cancer therapies in new orphan ... subscriptions from institutional and accredited investors for a ... of common stock and 3.35 million common stock ...
(Date:7/27/2015)... 27, 2015 Bloomage BioTechnology Corporation Limited ("Bloomage" ... cooperation with the South Korean BioTech Company Medytox Inc. ... Medybloom to develop and promote Type A Botulinum Toxin ... Medytox, the Botulinum Toxin brand, occupies ... the fourth company in the world successfully developed and ...
(Date:7/27/2015)...   DocResponse was ranked the most ... peer-reviewed study , "Evaluation of symptom checkers ... in the July issue of The British Medical ... School researchers determined that performance of online symptom ... diagnosis first in standardized patient evaluations more often ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 2Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 3Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3
... BEVERLY, Mass., March 8, 2011 Cellceutix Corporation (Pink ... has entered into a Confidential Disclosure Agreement (CDA) pertaining ... world,s largest pharmaceutical companies. Cellceutix CEO, ... to be signing a CDA on a compound before ...
... Inc. (Nasdaq: CPIX ), a specialty pharmaceutical ... announced fourth quarter and full year 2010 financial results. ... December 31, 2010, net revenue was $12.8 million, up 20% ... quarterly revenue growth was largely driven by 16% year-over-year growth ...
Cached Medicine Technology:Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 2Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 2Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 4Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 5Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 6Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 7Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 8Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 9Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 10Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 11Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 12Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 13
... The DNA Expert: Detection of PCR, cDNA and ... an optimal microplate reader for a variety applications ... The instrument is suitable to handle assays in ... PCR tubes Cuvettes ...
... From solution to cell based assays, in ... non-isotopic method of detection, Fusion is the ... plus the capability to use the AlphaScreen ... modes in one system: Reads AlphaScreen ...
This new dedicated VICTOR2 model is for fluorescence and luminescence measurements....
This a new dedicated VICTOR2 model for fluorescence, fluorescence polarization and luminescence measurement with stacker and robotic loading....
Medicine Products: